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analysis is required to evaluate the appropriateness of FFF in 
lung SBRT. 
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Purpose or Objective: An electromagnetic (ELM) system 
(Calypso, Varian Medical System, Palo Alto, CA, USA) based 
on sub-millimeter high frequency localization of three 
transponders permanently implanted in the prostate, was 
recently introduced for continuous real-time tracking of the 
tumor. Several studies of the tracks acquired over thousands 
of patients were reported in literature and allowed to give a 
detailed insight of intra-fraction prostate motion. Aim of this 
work was to develop and validate a tool to selectively filter 
the signal produced by the ELM transponders and to apply it 
for the evaluation of the amplitude of prostate motion only 
due to patient’s breathing. 
 
Material and Methods: To selectively filter the signal 
produced by ELM transponders a software was developed in 
the Matlab environment (version R2014b). Briefly, the 
developed software computes the power density spectrum 
(PDS) of the recorded tracks and isolates the ‘breathing 
peak’, i.e. the peak which is centered at the frequency 
corresponding to the breathing average frequency of each 
single analyzed session. A bandpass filter on the breathing 
peak is then applied to the original tracking data, in order to 
isolate the motion of the prostate due to the breathing of the 
patient. The software was validated with data recorded with 
QUASAR moving phantom, provided with an home-made 
insert of three transponders. Simulated breathing frequencies 
of 10, 12, 14, 16, 18, 20, 22 and 24 cycles per minute were 
recorded for at least one minute with the ELM system. After 
validation, tracks of 6 prostate patients who underwent EBRT 
were analyzed for a total of 180 treatments sessions. For 
each session, the corresponding maximum amplitude of 
prostate motion along the three main directions was 
obtained. Intra patients average data and standard deviations 
were reported along with the overall maximum amplitude. 
 
Results: For the in-phantom validation, the developed 
software automatically computed the correct cycles per 
minute within a 0.52% uncertainty. The average amplitudes 
of prostate motion due to patient’s breathing are listed in 
Table 1. As expected, the smallest motion resulted in left-
right direction. The limited standard deviations indicate a 
low intra-patient motion variability. For each patient, the 
overall maximum amplitude turned out to be not negligible, 
but at the same time less than 0.5 mm. 
 
Conclusion: A tool to quantify prostate motion due to 
patient’s breathing was successfully developed, validated and 
applied to a consistent number of treatments sessions. 
Although small compared to the motion caused by the 
modifications of near organs (i.e. bladder and rectum), the 
achieved results show that the motion associated to patient’s 
breathing should be carefully considered in the definition of 
an adequate Internal Target Volume. 
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Purpose or Objective: In proton therapy treatments of 
intraocular tumors, patients actively participate by fixating a 
red diode, prepositioned according to planning prescriptions, 
to stabilize gaze direction. This work aims to evaluate safety 
margins effectiveness against involuntary eye movement that 
may occur in the course of the treatment. 
 
Material and Methods: A custom eye tracking system (ETS), 
able to monitor eye position and orientation through 3D 
video-oculography techniques, was installed in a proton 
therapy (PT) treatment room (fig.1). All ocular PT centers 
are equipped with an in-room orthogonal X-ray imaging 
system used to verify treatment geometry. Tantalum radio-
opaque markers, sutured to the sclera of the diseased eye, 
aid to determine the gaze angle of the eye during simulation, 
and the correct eye position at treatment. During simulation, 
the ETS monitored the eye simultaneously with X-ray 
acquisition to assess the tantalum markers pose relative to 
eye position and orientation. As a result, the ETS was able to 
assess eye motion and markers position in physical 
coordinates during dose delivery. 
A first analysis was performed on two patients with three and 
two monitored treatment fraction respectively. Both patients 
had four implanted markers. To enable 3D localization of 
markers identified in X-ray images, the geometry of the 
imaging system was calibrated by means of the Direct Linear 
Transform (DLT) algorithm. We measured the distance 
between markers 3D position seen by the ETS during 
irradiation and identified on setup verification X-ray images 
acquired prior dose delivery to quantify intra-fraction eye 
motion. Margins expansions of 2.5 mm were applied laterally 
and distally. Median, interquartile range (IQR) and maximum 
values for the clip-to-clip distance are reported in table 1.  
 
